ICT1 Antibody

Immature Colon Carcinoma Transcript 1 (ICT1) is a gene that has garnered significant attention in cancer research due to its involvement in various types of cancers, including colorectal and gastric cancers. This article delves into the background of ICT1, its role in cancer progression, and the significance of mouse anti-human ICT1 antibodies in research.

ICT1 is a component of the human mitoribosome, which is essential for mitochondrial protein synthesis. It was initially identified in studies comparing undifferentiated and differentiated human colon carcinoma cell lines . ICT1 has peptidyl-tRNA hydrolase (PTH) activity, which is crucial for maintaining mitochondrial function .

Colorectal Cancer

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. ICT1 has been found to be highly expressed in colorectal cancer tissues, and its expression correlates with poor prognosis and reduced survival rates . Studies have shown that silencing ICT1 in CRC cells leads to decreased cell viability, inhibited cell migration, and induced apoptosis . These findings suggest that ICT1 could be a potential target for CRC diagnosis and treatment.

Gastric Cancer

Gastric cancer is another malignancy where ICT1 plays a significant role. ICT1 is overexpressed in gastric cancer tissues, and its knockdown has been shown to inhibit cell proliferation and induce apoptosis in gastric cancer cells . The mechanism involves cell-cycle arrest and activation of apoptotic pathways, highlighting ICT1’s potential as a therapeutic target in gastric cancer .

Mouse anti-human ICT1 antibodies are crucial tools in cancer research. These antibodies are used to detect and quantify ICT1 expression in various cancer tissues through techniques like immunohistochemistry and flow cytometry. By targeting ICT1, researchers can better understand its role in cancer progression and develop targeted therapies.